164 related articles for article (PubMed ID: 35244678)
1. Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma.
Peres LC; Colin-Leitzinger C; Sinha S; Marks JR; Conejo-Garcia JR; Alberg AJ; Bandera EV; Berchuck A; Bondy ML; Christensen BC; Cote ML; Doherty JA; Moorman PG; Peters ES; Moran Segura C; Nguyen JV; Schwartz AG; Terry PD; Wilson CM; Fridley BL; Schildkraut JM
Cancer Epidemiol Biomarkers Prev; 2022 May; 31(5):1006-1016. PubMed ID: 35244678
[TBL] [Abstract][Full Text] [Related]
2. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.
Zhang G; Xu Q; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Cancer Med; 2021 Jun; 10(12):3905-3918. PubMed ID: 33955198
[TBL] [Abstract][Full Text] [Related]
3. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
; Goode EL; Block MS; Kalli KR; Vierkant RA; Chen W; Fogarty ZC; Gentry-Maharaj A; Tołoczko A; Hein A; Bouligny AL; Jensen A; Osorio A; Hartkopf A; Ryan A; Chudecka-Głaz A; Magliocco AM; Hartmann A; Jung AY; Gao B; Hernandez BY; Fridley BL; McCauley BM; Kennedy CJ; Wang C; Karpinskyj C; de Sousa CB; Tiezzi DG; Wachter DL; Herpel E; Taran FA; Modugno F; Nelson G; Lubiński J; Menkiszak J; Alsop J; Lester J; García-Donas J; Nation J; Hung J; Palacios J; Rothstein JH; Kelley JL; de Andrade JM; Robles-Díaz L; Intermaggio MP; Widschwendter M; Beckmann MW; Ruebner M; Jimenez-Linan M; Singh N; Oszurek O; Harnett PR; Rambau PF; Sinn P; Wagner P; Ghatage P; Sharma R; Edwards RP; Ness RB; Orsulic S; Brucker SY; Johnatty SE; Longacre TA; Ursula E; McGuire V; Sieh W; Natanzon Y; Li Z; Whittemore AS; Anna A; Staebler A; Karlan BY; Gilks B; Bowtell DD; Høgdall E; Candido dos Reis FJ; Steed H; Campbell IG; Gronwald J; Benítez J; Koziak JM; Chang-Claude J; Moysich KB; Kelemen LE; Cook LS; Goodman MT; García MJ; Fasching PA; Kommoss S; Deen S; Kjaer SK; Menon U; Brenton JD; Pharoah PDP; Chenevix-Trench G; Huntsman DG; Winham SJ; Köbel M; Ramus SJ
JAMA Oncol; 2017 Dec; 3(12):e173290. PubMed ID: 29049607
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of tumor infiltrating lymphocytes in high-grade serous ovarian carcinoma].
Huang XM; Zhang Y; Xu L; Wang M; Wang W
Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):610-614. PubMed ID: 31422591
[No Abstract] [Full Text] [Related]
5. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune cell clustering and its association with survival in African American women with ovarian cancer.
Wilson C; Soupir AC; Thapa R; Creed J; Nguyen J; Segura CM; Gerke T; Schildkraut JM; Peres LC; Fridley BL
PLoS Comput Biol; 2022 Mar; 18(3):e1009900. PubMed ID: 35235563
[TBL] [Abstract][Full Text] [Related]
7. Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population.
Corey L; Cote ML; Ruterbusch JJ; Vezina A; Winer I
Am J Obstet Gynecol; 2022 Apr; 226(4):541.e1-541.e13. PubMed ID: 34736911
[TBL] [Abstract][Full Text] [Related]
8. High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer.
Ölmez F; Oğlak SC; Ölmez ÖF; Akbayır Ö; Yılmaz E; Akgöl S; Konal M; Seyhan NA; Kinter AK
Turk J Obstet Gynecol; 2022 Sep; 19(3):246-256. PubMed ID: 36149309
[TBL] [Abstract][Full Text] [Related]
9. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).
Pizarro D; Romero I; Pérez-Mies B; Redondo A; Caniego-Casas T; Carretero-Barrio I; Cristóbal E; Gutiérrez-Pecharromán A; Santaballa A; D'Angelo E; Hardisson D; Vieites B; Matías-Guiu X; Estévez P; Guerra E; Prat J; Poveda A; López-Guerrero JA; Palacios J
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446361
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer.
Hoffmann I; Dragomir MP; Monjé N; Keunecke C; Kunze CA; Schallenberg S; Marchenko S; Schmitt WD; Kulbe H; Sehouli J; Braicu IE; Jank P; Denkert C; Darb-Esfahani S; Horst D; Sinn BV; Sers C; Bischoff P; Taube ET
Neoplasia; 2023 Oct; 44():100934. PubMed ID: 37703626
[TBL] [Abstract][Full Text] [Related]
12. Racial and ethnic differences in the adoption of opportunistic salpingectomy for ovarian cancer prevention in the United States.
Karia PS; Huang Y; Tehranifar P; Visvanathan K; Wright JD; Genkinger JM
Am J Obstet Gynecol; 2022 Aug; 227(2):257.e1-257.e22. PubMed ID: 35489439
[TBL] [Abstract][Full Text] [Related]
13. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
14. Racial Disparities in Survival Outcomes of Patients With Serous Epithelial Ovarian Cancer: A Retrospective Cohort Analysis.
Shingala K; Stavros S; Parag S; Tercek A; Makhani SS; Bouz A; Galbo A; Chung-Bridges K
Cureus; 2023 Jan; 15(1):e34389. PubMed ID: 36874646
[TBL] [Abstract][Full Text] [Related]
15. Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer.
James FR; Jiminez-Linan M; Alsop J; Mack M; Song H; Brenton JD; Pharoah PDP; Ali HR
BMC Cancer; 2017 Sep; 17(1):657. PubMed ID: 28931370
[TBL] [Abstract][Full Text] [Related]
16. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract][Full Text] [Related]
17. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis.
Yang B; Li X; Zhang W; Fan J; Zhou Y; Li W; Yin J; Yang X; Guo E; Li X; Fu Y; Liu S; Hu D; Qin X; Dou Y; Xiao R; Lu F; Wang Z; Qin T; Wang W; Zhang Q; Li S; Ma D; Mills GB; Chen G; Sun C
Cell Rep Med; 2022 Dec; 3(12):100856. PubMed ID: 36543113
[TBL] [Abstract][Full Text] [Related]
18. CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
Tubridy EA; Eiva MA; Liu F; Omran DK; Gysler S; Brown EG; Roy AG; Zeng Y; Oh J; Cao Q; Gitto SB; Powell DJ
Gynecol Oncol; 2024 Jan; 184():74-82. PubMed ID: 38290413
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection.
Chen KJ; Zhou L; Xie HY; Ahmed TE; Feng XW; Zheng SS
Med Oncol; 2012 Sep; 29(3):1817-26. PubMed ID: 21678026
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
